Here are three biotech layoffs Becker’s has reported on since Sept. 12:
- In September, 2seventybio, which makes T-cell drugs for cancer treatment, laid off 176 employees, or 40% of its workforce.
- In October, Sana Biotechnology, a cell and gene therapy company, laid off 29% of its workforce as it looks to focus on its ex vivo cell therapy line.
- In November, Sangamo Therapeutics, a company focusing on the treatment of genetic conditions, laid off 40% of its workforce and closed down its headquarters.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
